This variation can potentially affect how the medication works in your body
Key Highlights: 48 PSGs for products with no approved ANDAs (25 complex products) 39 PSGs for complex products (6 new, 33 revised) Therapies for COPD, opioid overdose, type 2 diabetes, major depressive disorder, and more Notable PSGs: Ensifentrine inhalation suspension (COPD, RLD: OHTUVAYRE) Naloxone hydrochloride nasal spray (Opioid overdose, RLD: REZENOPY) Semaglutide oral tablet (Type 2 diabetes, RLD: RYBELSUS) Trazodone hydrochloride ER oral tablet (MDD, RLD: OLEPTRO) Link : By publishing PSGs, FDA continues to promote innovation in generic development while advancing public health and patient access to cost-effective medicines
Gastrointestinal side effects, including constipation, nausea, and altered bowel habits, occur frequently with these medicines
Risk of developing each substance use disorder also declined significantly by 18% for alcohol, 14% for cannabis, 20% for cocaine and nicotine, and 25% for opioids